MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Net decrease in cashand cash...-$167,292K Accounts payable andaccrued expenses$34,104K Stock-based compensation$28,719K Accrued interest onrevenue interest...$24,333K Prepaid expenses andother current assets-$5,513K Other-$5,205K Accruedpayment-in-kind interest on debt$4,664K Amortization of debt discount$3,014K Depreciation andamortization$633K Inventory reserve$280K Operating right-of-useassets and lease...$222K Accrued interest$121K Proceeds from issuance ofcommon stock from...$1,638K Net cash used inoperating activities-$166,775K Net cash (used in)provided by financing...-$288K Net cash used ininvesting activities-$229K Canceled cashflow$106,808K Canceled cashflow$1,638K Net loss-$221,247K Payment of employee taxobligations related to...-$1,926K Cash paid forproperty and equipment$229K Accounts receivable, net$39,331K Inventory$11,781K Other long-termassets$1,224K
Cash Flow
source: myfinsight.com

Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. (PHAT)